Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Noven Pharmaceuticals has signed global license and supply agreements with Procter & Gamble Pharmaceuticals, a subsidiary of The Procter & Gamble Company, relating to the development and commercialization of prescription transdermal patches for the treatment of hypoactive sexual desire disorder in women.
Subscribe to our email newsletter
Under the agreements, Noven has granted Procter & Gamble Pharmaceuticals (P&GP) an exclusive worldwide license to a testosterone patch for the treatment of hypoactive sexual desire disorder (HSDD) in women, as well as potential next-generation patches in the same therapeutic category.
The agreements provide for payment to Noven of royalties and manufacturing fees, as well as development and sales milestones, relating to the licensed products. P&GP will fund any clinical development costs and will be responsible for any regulatory filings and marketing applications associated with the licensed products, as applicable.
Noven successfully formulated the licensed testosterone patch utilizing its patented Dot Matrix transdermal delivery technology pursuant to a development agreement between Noven and P&GP established in 2003.
Peter Brandt, president and CEO of Noven, said: “We are excited to be advancing our collaboration with one of the world’s best-regarded companies to bring advanced Dot Matrix patches to women suffering from HSDD.”